Eisai Clinical Trials

A 15-week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer’s Disease.


Study Overview

Not available
Dec 1993 - May 1995
Alzheimer's disease
The primary efficacy endpoint was to evaluate the efficacy (primary efficacy parameters included ADAS-cog and CIBI-C Plus) of two oral dose levels of E2020, 5mg/day and 10mg/day, versus Placebo, in patients with Alzheimer's  Disease.

  • Males and females (age 50 years and over)

  • Completed

  • Phase 3

  • United States


CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158:1021-31.

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Sample CRF
Full CSR